Management of Recurrent Malignant Pleural Effusion with Chemical Pleurodesis

Kılıç, Dalokay; Akay, Hadı; Kavukçu, Şevket; Kutlay, Hakan; Cangır, Ayten; Enön, Serkan; Kadılar, Cem

doi:10.1007/s00595-005-2996-5

Cited by 35 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prognosis following detection of MPE is generally poor, with reported median survivals of 3 (lung cancer) to 12 (breast cancer) months (5,7), and 1-month mortality rates ranging from 29% to 54% (24,25). In this study, the median survival from date of MP was 5.2 months, while the 1-month mortality rate of 19% was lower than in previous studies.…”

Section: Discussioncontrasting

confidence: 57%

A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

Sreter¹,

Jakopović

Janevski

et al. 2016

Ann. Transl. Med.

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 57%

A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

Sreter¹,

Jakopović

Janevski

et al. 2016

Ann. Transl. Med.

View full text Add to dashboard Cite

“…Talc has been reported as safe and efficacious for pleurodesis [15][16][17][18][19][20][21][22][23]. A Cochrane review reported that pleurodesis with talc provided the highest relative chance of MPE nonrecurrence when compared with bleomycin, tetracycline, mustine or chest-tube drainage alone [24].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients

Hirata¹,

Yonemori

Hirakawa³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

This study retrospectively compared long-term outcomes between two groups of breast cancer patients with malignant pleural effusion (MPE): those receiving only systemic therapy (ST) and those receiving ST following initial pleurodesis (P-ST).We identified 180 breast cancer patients from the National Cancer Center Hospital (Tokyo, Japan) database who had received ST and P-ST as an initial treatment for MPE between 1997 and 2008 for study inclusion. Pleural progression-free survival (PPFS) was defined as the time from ST in the ST group and from pleurodesis in the P-ST group to the first observation of pleural progression or death from any cause.Of the 180 patients, 78 received ST and 102 received P-ST after MPE diagnosis. Median duration of follow-up was 12.7 months (range 0.9-80.1 months). Median PPFS for the ST group and the P-ST group was 4.1 and 8.5 months, respectively. The difference in PPFS between the two groups was statistically significant (p,0.001) and the hazard ratio after adjusting for prognostic factors in the P-ST group relative to the ST group was 0.24.Our results suggest that the efficacy of P-ST may be superior to that of ST alone with respect to local control of pleural effusions in breast cancer patients.

show abstract

“…First, the number of cases was relatively small; therefore, further studies with more patients are needed. Second, there was possible bias due to the different CT methods used (i.e., use agement of malignant pericardial effusion has not yet been established [17,18], identification and prompt control of malignant pericardial effusion can dramatically alleviate symptoms, allowing continued systemic therapy and improvement of survival from an otherwise controllable disease [19].…”

Section: Ct Of Pericardial Effusionmentioning

confidence: 99%

CT Findings in Patients With Pericardial Effusion: Differentiation of Malignant and Benign Disease

Sun

Park

Kang³

2010

American Journal of Roentgenology

View full text Add to dashboard Cite

Management of Recurrent Malignant Pleural Effusion with Chemical Pleurodesis

Abstract: Talc resulted in the earliest expansion, minimal drainage, and the earliest tube and catheter removal.

Cited by 35 publications

References 27 publications

A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

A pilot study—is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients

CT Findings in Patients With Pericardial Effusion: Differentiation of Malignant and Benign Disease

Contact Info

Product

Resources

About